CanaQuest Medical Corp.

CANQF

CA1372201097

Pharmaceuticals

Market Closed - OTC Markets Other stock markets 12:25:48 14/05/2024 am IST			5-day change	1st Jan Change
0.1098 ^USD	-0.09%		-21.52%	-54.25%

2023	NHL Alumni Association Partners with CanaQuest and NEEKA Health to Conduct Studies for Anxiety and Quality of Life in Former NHL Players	CI
2023	CanaQuest Medical Corp. cancelled the transaction announced on October 26, 2022	CI

CanaQuest Medical Corp. announced a financing transaction

October 26, 2022

CanaQuest Medical Corp. announced that it will receive $2,000,000 in a round of funding on October 26, 2022. The company will issue common stock in the transaction.

The company will issue securities pursuant to exemption provided under Regulation D.

Latest news about CanaQuest Medical Corp.

NHL Alumni Association Partners with CanaQuest and NEEKA Health to Conduct Studies for Anxiety and Quality of Life in Former NHL Players	31/23/31	CI
CanaQuest Medical Corp. cancelled the transaction announced on October 26, 2022	26/23/26	CI
CanaQuest Medical Corp. Announces Award of European Cannabinoid Patent	19/23/19	CI
CanaQuest Achieves Statistically Significant Reduction of Seizures for Epilepsy Compared to Standard CBD	08/22/08	CI
CanaQuest Medical Corp. announced a financing transaction	26/22/26	CI
CanaQuest Medical Corp. Launches Mentanine (R) (Cannabidiol + IP Formula) in the US	08/22/08	CI
CanaQuest Medical Corp. Appoints Rob Rinderman as New Director of Communications	07/21/07	CI
Canaquest Signs Medicinal Cannabis Education Partnership with the Canadian Cannabis Dispute Resolution Centre	11/21/11	CI
CANAQUEST MEDICAL CORP Announces New Production and Distribution Agreement with PurCann Pharma and SiliCycle Inc	02/21/02	CI
CanaQuest Medical Corp. Files A Provisional Cannabidiol/Omega-3 Patent, Trade Named Mentanine®	14/20/14	CI
CanaQuest Medical Corp Awaits Health Canada Approval for Sales and Export of Mentabinol®	06/20/06	CI
CanaQuest Medical Corp. will Change its Ticker to CANQ.F from ADYNF	08/19/08	CI
Algae Dynamics Corp Ordinary Shares will Change its Name to CanaQuest Medical Corporation Ordinary Shares	08/19/08	CI
Algae Dynamics Corp. announced that it has received CAD 0.1 million in funding	19/18/19	CI
Algae Dynamics Corp. announced that it has received CAD 0.52 million in funding	03/18/03	CI
Algae Dynamics Corp. Secures Bulk Cannabis Supply Agreement for Collaboration Partners	02/18/02	CI
Algae Dynamics Corp. announced that it has received $0.5 million in funding from Teewinot Life Sciences Corp.	15/17/15	CI
Algae Dynamics Corp. announced that it expects to receive $0.5 million in funding from Teewinot Life Sciences Corp.	27/17/27	CI
Algae Dynamics Corp. Enters into a Letter of Intent with Bonify to Produce Unique Cannabis Oil Products	16/17/16	CI
Algae Dynamics Corp Announces Joint Venture with ARA- Avanti Rx Analytics Inc. to Formulate, Manufacture and Sell Products Utilizing Algae, Hemp Cannabis Oils	20/17/20	CI
Algae Dynamics Seeks Partner	16/17/16	CI
Algae Dynamics Corp Announces Research Agreement with University of Western Ontario to Investigate the Use of Cannabis Derivatives	13/17/13	CI
Algae Dynamics Corp. Announces Research Agreement with University of Waterloo to Investigate Use of Cannabis Oil in the Context of Cancer	25/17/25	CI
Algae Dynamics Corp. Auditor Raises 'Going Concern' Doubt	05/16/05	CI
Algae Dynamics Corp. announced that it has received $0.03 million in funding from RY Capital Group, LLC.	02/15/02	CI

CanaQuest Medical Corporation is a Canada-based clinical-stage, life sciences company. The Company is focused on the drug discovery and development of targeted therapeutics within the endocannabinoid system and specific brain receptors. The Company is also focused on treating neurological conditions, such as epilepsy, anxiety, depression, and Post Traumatic Stress Disorder (PTSD), including addiction. It provides a novel master formulation derived from cannabidiol (CBD) + IP formula. The Company has a drug candidate, CQ-001, which is positioned for clinical trials, targeting epilepsy. An OTC version of the master formulation, branded as Mentanine, is available for sale via the Companyâs store in the United States. Its non-psychoactive properties provide a safe and effective alternative to traditional treatments with minimal effects. The Companyâs wholly owned subsidiary is ADC BioMedical Corp.

Sector

Pharmaceuticals

More about the company

Sector Alternative Medicine

	1st Jan change	Capi.
CANAQUEST MEDICAL CORP.	-54.25%	2.35M
DONG-E-E-JIAO CO.,LTD.	+43.17%	6.16B
SHIJIAZHUANG YILING PHARMACEUTICAL CO., LTD.	-14.69%	4.46B
TASLY PHARMACEUTICAL GROUP CO., LTD	-8.17%	3.27B
TIANJIN PHARMACEUTICAL DA REN TANG GROUP CORPORATION LIMITED	+6.95%	3.2B
SHANDONG BUCHANG PHARMACEUTICALS CO., LTD.	-1.76%	2.6B
HENAN LINGRUI PHARMACEUTICAL CO., LTD.	+50.20%	1.98B
GUANGYUYUAN CHINESE HERBAL MEDICINE CO., LTD.	-7.85%	1.7B
TIBET CHEEZHENG TIBETAN MEDICINE CO., LTD.	-0.40%	1.66B
TIANJIN CHASE SUN PHARMACEUTICAL CO.,LTD	-9.91%	1.61B

Alternative Medicine